[{"id":"efccfeae-b1d6-4b39-873a-d9182d5a3bf3","acronym":"NRG-BR004","url":"https://clinicaltrials.gov/study/NCT03199885","created_at":"2021-01-18T15:46:49.625Z","updated_at":"2025-02-25T12:26:43.973Z","phase":"Phase 3","brief_title":"Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT03199885 - NRG-BR004","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PGR • IL2","pipe":" | ","alterations":" HER-2 positive","tags":["ER • PGR • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tecentriq (atezolizumab) • paclitaxel • docetaxel • Perjeta (pertuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • Paletan (pertuzumab biosimilar) • EG1206A (pertuzumab biosimilar) • GB221 (coprelotamab) • HS627 (pertuzumab biosimilar) • Pertuvia (pertuzumab biosimilar) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 04/05/2019","start_date":" 04/05/2019","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 05/15/2025","study_completion_date":" 05/15/2025","last_update_posted":"2024-09-26"},{"id":"130d64cc-8174-4099-9fdc-c77e00468d6c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02003209","created_at":"2021-01-18T09:08:50.149Z","updated_at":"2024-07-02T16:35:02.395Z","phase":"Phase 3","brief_title":"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer","source_id_and_acronym":"NCT02003209","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" TILs","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • goserelin acetate • Herwenda (trastuzumab biosimilar) • Paletan (pertuzumab biosimilar) • EG1206A (pertuzumab biosimilar) • GB221 (coprelotamab) • HS627 (pertuzumab biosimilar) • Pertuvia (pertuzumab biosimilar) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 01/15/2014","start_date":" 01/15/2014","primary_txt":" Primary completion: 10/31/2016","primary_completion_date":" 10/31/2016","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-21"},{"id":"a9684336-5d63-4acc-ae74-f11a14cd8023","acronym":"","url":"https://clinicaltrials.gov/study/NCT04514419","created_at":"2021-01-18T21:38:06.480Z","updated_at":"2025-02-25T12:27:41.307Z","phase":"Phase 3","brief_title":"Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel","source_id_and_acronym":"NCT04514419","lead_sponsor":"Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • HS627 (pertuzumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 408","initiation":"Initiation: 06/30/2020","start_date":" 06/30/2020","primary_txt":" Primary completion: 11/20/2021","primary_completion_date":" 11/20/2021","study_txt":" Completion: 11/20/2021","study_completion_date":" 11/20/2021","last_update_posted":"2020-08-17"}]